Are Peptides Legal in Iowa? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Iowa as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Iowa attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Iowa statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Iowa has scheduled or banned on its own. The Iowa Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Iowa at a glance

State controlled-substances law: Iowa Code chapter 124 (Uniform Controlled Substances Act); schedules at §§ 124.204, 124.206, 124.208, 124.210 and 124.212 (legis.iowa.gov)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (Iowa Code § 124.208 (Schedule III)) (legis.iowa.gov)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: Board of Pharmacy rule 481 IAC 552.22(2) prohibits compounding a preparation that is essentially a copy of an FDA-approved drug unless the prescriber documents a clinically significant difference for the individual patient or the approved product is on the FDA shortage list, and the prescription must document the change. It applies to semaglutide and tirzepatide copies without naming them. No separate Iowa statement on salt forms was found (2025-08) (legis.iowa.gov)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. Board of Medicine rule 481 IAC 655.9 lets a valid physician-patient relationship be formed through a telemedicine encounter and waives the in-person interview and examination when the technology is sufficient to reach an informed diagnosis; it prohibits prescribing based solely on an internet request or a static internet questionnaire (an adaptive, interactive online interview is allowed) and prescribing on a phone call alone without an existing relationship. (legis.iowa.gov)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Iowa, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Iowa:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Iowa. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Iowa law adds

Iowa's controlled-substances law (Iowa Code chapter 124 (Uniform Controlled Substances Act); schedules at §§ 124.204, 124.206, 124.208, 124.210 and 124.212) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (legis.iowa.gov)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Iowa's schedules or in a Iowa-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Schedule III lists anabolic steroids only; the section contains no reference to human growth hormone, somatropin or chorionic gonadotropin. HGH is an ordinary prescription drug under Iowa Code chapter 155A, with the federal HGH statute on top. (Iowa Code § 124.208 (Schedule III)) (legis.iowa.gov)

Compounded semaglutide and tirzepatide

2025-08. Board of Pharmacy rule 481 IAC 552.22(2) prohibits compounding a preparation that is essentially a copy of an FDA-approved drug unless the prescriber documents a clinically significant difference for the individual patient or the approved product is on the FDA shortage list, and the prescription must document the change. It applies to semaglutide and tirzepatide copies without naming them. No separate Iowa statement on salt forms was found. (legis.iowa.gov)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Iowa medical board guidance specific to peptide therapy was located. A Iowa prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Iowa

Iowa's stand-alone offence for possessing a prescription drug without a prescription (Iowa Code § 155A.21) was repealed in 2024, so an individual holding an unscheduled research peptide commits no Iowa offence; § 155A.24 still makes selling, giving away or administering a non-controlled prescription drug outside the chapter a serious misdemeanor, so the exposure sits with sellers. (legis.iowa.gov)

Ordering from a vendor in another state. Almost every research-peptide order into Iowa is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Board of Medicine rule 481 IAC 655.9 lets a valid physician-patient relationship be formed through a telemedicine encounter and waives the in-person interview and examination when the technology is sufficient to reach an informed diagnosis; it prohibits prescribing based solely on an internet request or a static internet questionnaire (an adaptive, interactive online interview is allowed) and prescribing on a phone call alone without an existing relationship. (legis.iowa.gov) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Iowa law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Iowa

2025-02-19. Iowa's attorney general signed the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. HSB 591, which would put medspas that dispense compounded GLP-1s under Board of Pharmacy licensing, had only cleared a House subcommittee as of February 2026. No Iowa attorney general or board enforcement against peptide sellers or medspas was found.

Frequently asked questions

Is BPC-157 legal in Iowa?

Iowa has not scheduled BPC-157, so possessing it is not a Iowa offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Iowa?

Yes. Board of Medicine rule 481 IAC 655.9 lets a valid physician-patient relationship be formed through a telemedicine encounter and waives the in-person interview and examination when the technology is sufficient to reach an informed diagnosis; it prohibits prescribing based solely on an internet request or a static internet questionnaire (an adaptive, interactive online interview is allowed) and prescribing on a phone call alone without an existing relationship. The Iowa Board of Pharmacy position on compounded versions: Board of Pharmacy rule 481 IAC 552.22(2) prohibits compounding a preparation that is essentially a copy of an FDA-approved drug unless the prescriber documents a clinically significant difference for the individual patient or the approved product is on the FDA shortage list, and the prescription must document the change. It applies to semaglutide and tirzepatide copies without naming them. No separate Iowa statement on salt forms was found.

Is HGH legal in Iowa?

Only with a valid prescription for an approved use. Iowa does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Iowa fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.